Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
ViaDerma, Inc. Provides Preliminary Revenue Estimates and Highlights for its Record Breaking 1st Quarter | ||
By: GlobeNewswire - 08 Apr 2021 | Back to overview list |
|
The Company realized significant Q1 revenue growth due to increased online retail sales and proceeds from a licensing agreement LOS ANGELES, April 08, 2021 (GLOBE NEWSWIRE) -- ViaDerma, Inc., (“Company”) (OTC Pink: VDRM), is pleased to provide an update of estimated sales and revenue numbers for the first quarter of 2021, as well as additional highlights of the Company’s year to date progress.
“While I am very pleased with the growth we have experienced in the first quarter, we have not yet even scratched the surface of our potential,” said Dr. Chris Otiko, ViaDerma President and CEO. “Vitastem is a great product and the results experienced by its users is likely the main reason for our increased online retail sales. However, our top priority this year is to focus on large institutions and integrated delivery networks. Our marketing reps have been working closely with several prospective institutional clients and we hope to finalize some large purchase orders in the near future.” About ViaDerma, Inc. Any forecast of future performance is a "forward looking statement" under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment. Contact information: |
||
|
||
Copyright 2021 GlobeNewswire | Back to overview list |